Signatera™ Designed on Genome:

Ultrasensitive ctDNA detection from the leaders in MRD testing

Learn More

Why Signatera™ Designed on Genome?

Ultra-sensitive limit of detection (LoD) down to low single digit PPM
Increased lead times and enhanced sensitivity to detect recurrence
Back by Signatera™ experience in >1M samples

Signatera™’s mPCR-NGS approach

Sequences deeper on the most critical variants, providing the most personalized and clinically meaningful MRD signal

Ultra-deep sequencing (> 135,000x coverage for each selected variant)¹
Highly curated selection of 64 clonal variants for optimized balance of ultra-sensitivity and high specificity¹
Proprietary variant selection and calling algorithms for bespoke MRD monitoring¹

Natera has the most comprehensive portfolio on MRD solutions to support patient care

Signatera™

Most extensively validated, adopted, and reimbursed MRD assay available

Signatera™ Designed on Genome

Lower limit of detection (LoD) for enhanced sensitivity and increased lead time to recurrence¹

Tissue Free MRD
(available in 2025)

Epigenomic assay with fast turnaround time for when tissue is not available

Same Signatera™ report; same sample requirements

Patient report: contains the same look and feel as existing Signatera™ report
Results will be identified as Signatera™ Genome
TAT: For initial result (4 weeks); 7-10 day TAT for subsequent results

SGN_LP_Genome_Webpage_1_537x416_20241213_NAT-8022014

^{*Can only be ordered for new patients (unable to convert existing orders)}

Set up a meeting with our medical science liaisons

Learn More

SGN_LP_Genome_Webpage_2_537x416_20241213_NAT-8022014

Signatera™ has the same sample requirements whether designed on genome or exome
Collect samples as usual and include the printed requisition in the kit

Signatera™ is the most extensively validated and widely adopted MRD assay

Widely Used by Clinicans

1 million

Signatera™ tests ordered by EOY 2024¹

>250,000+

Signatera™ patients¹

>40%

of oncologists¹

Extensive and Robust Clinical Evidence

>100

publications¹

>260

congress presentations & posters¹

>20

clinical studies prospectively using Signatera™¹

Is Signatera™ Designed on Genome, right for you?

We’re here to help you find out

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Natera data on file.

Signatera™ Designed on Genome:

Ultrasensitive ctDNA detection from the leaders in MRD testing

Why Signatera™ Designed on Genome?

Ultra-sensitive limit of detection (LoD) down to low single digit PPM

Increased lead times and enhanced sensitivity to detect recurrence

Back by Signatera™ experience in >1M samples

Signatera™’s mPCR-NGS approach

Sequences deeper on the most critical variants, providing the most personalized and clinically meaningful MRD signal

Ultra-deep sequencing (> 135,000x coverage for each selected variant)1

Highly curated selection of 64 clonal variants for optimized balance of ultra-sensitivity and high specificity1

Proprietary variant selection and calling algorithms for bespoke MRD monitoring1